ACE and psoriasis: As shown in Fig. 3, the analysis of the Asia subgroup showed that the ACE inhibitor user group had a higher risk of psoriasis incidence than the non-user group (OR 2.37, 95% CI 1.28–4.37), whereas the analysis of the Europe subgroup failed to show statistical significance.